Menu
Leagues and Governing Bodies

Tennis Grand Slams Will Pledge More Funds To Increase Drug Testing

The four Grand Slam tennis tournaments will "pledge a doubling of their financial contribution" to the sport's anti-doping program in a "major effort to stop potential cheating,” according to Mike Dickson of the London DAILY MAIL. A summit next Tuesday in N.Y. involving the game’s governing bodies and four Grand Slams is "expected to result in a considerable beefing up” of the anti-doping system. Wimbledon, the Australian Open, French Open and U.S. Open are “likely to put in extra funds as part of the biggest shake-up yet" for a program which conducted "only 21 out-of-competition blood tests" during '11. Tennis spends only $1.6M (all figures U.S.) per year “collecting samples across the whole sport.” The four Grand Slams currently are “believed to be putting in" around $150,000 each annually. No official numbers are available, but a source “put the anti-doping contributions of the ATP and WTA Tours at a mere” $326,000 each. The specific areas that will be increased will be "blood testing, out-of-competition tests in general and the introduction of biological passports, which check for alterations in a player’s blood make-up” (London DAILY MAIL, 2/26).

SHOW ME THE MONEY: USA TODAY’s Douglas Robson cites a USTA official as saying that the Grand Slams “would roughly double their current financial contribution from about $150,000 to $300,000 annually.” The ITF also will "increase its contribution to the fund, but it is unclear if the WTA and ATP Tour, which also help pay for the sport's anti-doping program, will increase their contributions.” In light of disgraced cyclist Lance Armstrong's admission of systemized doping, many top players “have expressed fears that authorities are not keeping up with those seeking an unfair advantage, especially with strength and stamina being pushed to new levels.” Tennis players such as Roger Federer, Andy Murray and Novak Djokovic “have called for increased testing, especially out-of-competition blood testing.” Next Tuesday's meeting “originally was slated for June but was pushed forward because of the growing sense that the sport is not using enough resources to track down potential cheaters” (USA TODAY, 2/28).

SBJ Morning Buzzcast: May 8, 2024

Start your morning with Buzzcast with Austin Karp: The NFL sets a date for its 2024 schedule release, while also dropping hints that it could soon approve private equity investment in teams; WNBA teams finally land charter flights; the F1 Miami Grand Prix delivers a record on TV; and Elevate lands in Happy Valley.

Phoenix Mercury/NBC’s Cindy Brunson, NBA Media Deal, Network Upfronts

On this week’s pod, SBJ’s Austin Karp chats with SBJ NBA writer Tom Friend about the pending NBA media Deal. Cindy Brunson of NBC and Phoenix Mercury is our Big Get this week. The sports broadcasting pioneer talks the upcoming WNBA season. Later in the show, SBJ media writer Mollie Cahillane gets us set for the upcoming network upfronts.

SBJ I Factor: Molly Mazzolini

SBJ I Factor features an interview with Molly Mazzolini. Elevate's Senior Operating Advisor – Design + Strategic Alliances chats with SBJ’s Ross Nethery about the power of taking chances. Mazzolini is a member of the SBJ Game Changers Class of 2016. She shares stories of her career including co-founding sports design consultancy Infinite Scale career journey and how a chance encounter while working at a stationery store launched her career in the sports industry. SBJ I Factor is a monthly podcast offering interviews with sports executives who have been recipients of one of the magazine’s awards.

Shareable URL copied to clipboard!

https://www.sportsbusinessjournal.com/Daily/Issues/2013/02/28/Leagues-and-Governing-Bodies/Tennis-Drugs.aspx

Sorry, something went wrong with the copy but here is the link for you.

https://www.sportsbusinessjournal.com/Daily/Issues/2013/02/28/Leagues-and-Governing-Bodies/Tennis-Drugs.aspx

CLOSE